Index
-
Market Cap
593.15M
Enterprise Value
-
Income
-
Sales
-
Book/sh
-
Cash/sh
-
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Sep 18, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
-
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-0.45
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Insider Own
38.62%
Insider Trans
18.57%
Inst Own
16.78%
Inst Trans
3.58%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
12.03%
SMA50
-1.53%
SMA200
-1.53%
Trades
Shs Outstand
62.77M
Shs Float
38.52M
52W High
15.50 -39.03%
52W Low
6.86 37.65%
Volatility
15.02% 10.65%
ATR (14)
1.01
RSI (14)
52.41
Beta
-
Rel Volume
0.65
Avg Volume
595.76K
Volume
385,207
Perf Week
18.57%
Perf Month
9.76%
Perf Quarter
-
Perf Half Y
-
Perf YTD
-37.00%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
7.99
Price
9.45
Change %
18.27%
Analysts 6 incl. previous ratings
Rating Distribution 6 Buy · 0 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Oct 26, 2026 Initiated H
Buy $30 +217.5% Oct 22, 2026 Initiated J JP Morgan
Overweight $36 +281.0% Oct 13, 2026 Initiated T TD Cowen
Buy Oct 13, 2026 Initiated J Jefferies
Buy $32 +238.6% Oct 13, 2026 Initiated E Evercore ISI
Outperform $36 +281.0% Oct 13, 2026 Initiated C
Overweight
Nov-04-26 08:00AM
Sep-30-26 08:23AM
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GORDON CARL L Director Nov 06 '26 Buy 7.85 49,416 387,916 5,230,578 Nov 10 08:14 PM GORDON CARL L Director Nov 10 '26 Buy 8.45 22,700 191,815 5,255,278 Nov 10 08:14 PM GORDON CARL L Director Nov 09 '26 Buy 8.24 20,000 164,800 5,234,578 Nov 10 08:14 PM ORBIMED ADVISORS LLC Director Nov 06 '26 Buy 7.85 49,416 387,916 5,230,578 Nov 10 08:09 PM ORBIMED ADVISORS LLC Director Nov 10 '26 Buy 8.45 22,700 191,815 5,255,278 Nov 10 08:09 PM ORBIMED ADVISORS LLC Director Nov 09 '26 Buy 8.24 20,000 164,800 5,234,578 Nov 10 08:09 PM GORDON CARL L Director Nov 03 '26 Buy 7.86 245,113 1,926,606 5,175,604 Nov 05 05:47 PM GORDON CARL L Director Nov 05 '26 Buy 7.31 156,091 1,141,025 5,220,762 Nov 05 05:47 PM GORDON CARL L Director Nov 04 '26 Buy 7.53 71,367 537,485 5,189,871 Nov 05 05:47 PM ORBIMED ADVISORS LLC Director Nov 03 '26 Buy 7.86 245,113 1,926,606 5,175,604 Nov 05 05:39 PM ORBIMED ADVISORS LLC Director Nov 05 '26 Buy 7.31 156,091 1,141,025 5,220,762 Nov 05 05:39 PM ORBIMED ADVISORS LLC Director Nov 04 '26 Buy 7.53 71,367 537,485 5,189,871 Nov 05 05:39 PM GORDON CARL L Director Sep 21 '26 Buy 15.00 1,333,333 19,999,995 5,126,891 Sep 23 05:35 PM ORBIMED ADVISORS LLC Director Sep 21 '26 Buy 15.00 1,333,333 19,999,995 5,126,891 Sep 23 05:29 PM
Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.
Pharm.D. Dr. Quehuong Dong M.B.A.
Chief Technology Officer Mr. Gary S. Koe Ph.D.
Ph.D. Dr. Kim-Hien Dao D.O.
Chief Financial Officer Mr. Christopher William Clark C.F.A.
Senior VP of Finance & Principal Accounting Officer Mr. David J. Tucker
E